Effective Nanoparticle-Based Nasal Vaccine Against Latent and Congenital Toxoplasmosis in Sheep

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2020 Oct 5

PMID 33013917

Citations 22

Authors

Celine Ducournau

Nathalie Moire

Rodolphe Carpentier

Pauline Cantin

Clement Herkt

Isabelle Lantier

Didier Betbeder

Isabelle Dimier-Poisson

Affiliations

Soon will be listed here.

Abstract

is a parasitic protozoan of worldwide distribution, able to infect all warm-blooded animals, but particularly sheep. Primary infection in pregnant sheep leads to millions of abortions and significant economic losses for the livestock industry. Moreover, infected animals constitute the main parasitic reservoir for humans. Therefore, the development of a One-health vaccine seems the best prevention strategy. Following earlier work, a vaccine constituted of total extract of proteins (TE) associated with maltodextrin nanoparticles (DGNP) was developed in rodents. In this study we evaluated the ability of this vaccine candidate to protect against latent and congenital toxoplasmosis in sheep. After two immunizations by either intranasal or intradermal route, DGNP/TE vaccine generated specific Th1-cellular immune response, mediated by APC-secretion of IFN-γ and IL-12. Secretion of IL-10 appeared to regulate this Th1 response for intradermally vaccinated sheep but was absent in intranasally-vaccinated animals. Finally, protection against latent toxoplasmosis and transplacental transmission were explored. Intranasal vaccination led to a marked decrease of brain cysts compared with the non-vaccinated group. This DGNP/TE vaccine administered intranasally conferred a high level of protection against latent toxoplasmosis and its transplacental transmission in sheep, highlighting the potential for development of such a vaccine for studies in other species.

Citing Articles

T-cell activation of Toxoplasma gondii positive donors by maltodextrin nanoparticles formulated with killed Toxoplasma gondii.

Vargas-Montes M, Fasquelle F, Cardona N, Gomez-Marin J, Betbeder D BMC Infect Dis. 2025; 25(1):279.

PMID: 40011842 PMC: 11866635. DOI: 10.1186/s12879-025-10656-5.

Inactivated nanovaccine boosts T-cell memory response in a seropositive yellow-footed rock wallaby () - A case report from Copenhagen Zoo.

Ogonczyk-Makowska D, Fasquelle F, Vreulx A, Scuotto A, Degraeve A, Thiroux B Int J Parasitol Parasites Wildl. 2024; 25:101017.

PMID: 39634323 PMC: 11614859. DOI: 10.1016/j.ijppaw.2024.101017.

Multilayer Nanocarrier for the Codelivery of Interferons: A Promising Strategy for Biocompatible and Long-Acting Antiviral Treatment.

Ramos T, Villacis-Aguirre C, Sandoval F, Martin-Solano S, Manrique-Suarez V, Rodriguez H Pharmaceutics. 2024; 16(11).

PMID: 39598474 PMC: 11597830. DOI: 10.3390/pharmaceutics16111349.

Nanoparticles with a Lipid Core Can Enhance the Infection of Epithelial Cells with an Enterovirus.

Vergez I, Nekoua M, Rubrecht C, Fasquelle F, Scuotto A, Alidjinou E Intervirology. 2024; 67(1):99-105.

PMID: 39068921 PMC: 11524536. DOI: 10.1159/000539601.

Spiramycin-loaded maltodextrin nanoparticles as a promising treatment of toxoplasmosis on murine model.

Abdel-Wahab A, Shafey D, Selim S, Sharaf S, Mohsen K, Allam D Parasitol Res. 2024; 123(7):286.

PMID: 39046555 PMC: 11269460. DOI: 10.1007/s00436-024-08280-4.

References

Kur J, Holec-Gasior L, Hiszczynska-Sawicka E . Current status of toxoplasmosis vaccine development. Expert Rev Vaccines. 2009; 8(6):791-808. DOI: 10.1586/erv.09.27. View

Hiszczynska-Sawicka E, Li H, Xu J, Holec-Gasior L, Kur J, Sedcole R . Modulation of immune response to Toxoplasma gondii in sheep by immunization with a DNA vaccine encoding ROP1 antigen as a fusion protein with ovine CD154. Vet Parasitol. 2011; 183(1-2):72-8. DOI: 10.1016/j.vetpar.2011.06.010. View

Buxton D, Thomson K, Maley S, Wright S, Bos H . Vaccination of sheep with a live incomplete strain (S48) of Toxoplasma gondii and their immunity to challenge when pregnant. Vet Rec. 1991; 129(5):89-93. DOI: 10.1136/vr.129.5.89. View

Verhelst D, De Craeye S, Vanrobaeys M, Czaplicki G, Dorny P, Cox E . Seroprevalence of Toxoplasma gondii in domestic sheep in Belgium. Vet Parasitol. 2014; 205(1-2):57-61. DOI: 10.1016/j.vetpar.2014.07.001. View

Buxton D, Innes E . A commercial vaccine for ovine toxoplasmosis. Parasitology. 1995; 110 Suppl:S11-6. DOI: 10.1017/s003118200000144x. View

Verhelst D, De Craeye S, Entrican G, Dorny P, Cox E . Parasite distribution and associated immune response during the acute phase of Toxoplasma gondii infection in sheep. BMC Vet Res. 2014; 10:293. PMC: 4279818. DOI: 10.1186/s12917-014-0293-5. View

Paillard A, Passirani C, Saulnier P, Kroubi M, Garcion E, Benoit J . Positively-charged, porous, polysaccharide nanoparticles loaded with anionic molecules behave as 'stealth' cationic nanocarriers. Pharm Res. 2009; 27(1):126-33. PMC: 2901554. DOI: 10.1007/s11095-009-9986-z. View

Ducournau C, Nguyen T, Carpentier R, Lantier I, Germon S, Precausta F . Synthetic parasites: a successful mucosal nanoparticle vaccine against Toxoplasma congenital infection in mice. Future Microbiol. 2017; 12:393-405. DOI: 10.2217/fmb-2016-0146. View

Hiszczynska-Sawicka E, Oledzka G, Holec-Gasior L, Li H, Xu J, Sedcole R . Evaluation of immune responses in sheep induced by DNA immunization with genes encoding GRA1, GRA4, GRA6 and GRA7 antigens of Toxoplasma gondii. Vet Parasitol. 2011; 177(3-4):281-9. DOI: 10.1016/j.vetpar.2010.11.047. View

10.

Wilkins M, OConnell E, Te Punga W . Toxoplasmosis in sheep. I. Effect of a killed vaccine on lambing losses caused by experimental challenge with Toxoplasma gondii. N Z Vet J. 1987; 35(3):31-4. DOI: 10.1080/00480169.1987.35371. View

11.

Innes E, Panton W, Sanderson A, Thomson K, Wastling J, Maley S . Induction of CD4+ and CD8+ T cell responses in efferent lymph responding to Toxoplasma gondii infection: analysis of phenotype and function. Parasite Immunol. 1995; 17(3):151-60. DOI: 10.1111/j.1365-3024.1995.tb01017.x. View

12.

Bernocchi B, Carpentier R, Lantier I, Ducournau C, Dimier-Poisson I, Betbeder D . Mechanisms allowing protein delivery in nasal mucosa using NPL nanoparticles. J Control Release. 2016; 232:42-50. PMC: 4907310. DOI: 10.1016/j.jconrel.2016.04.014. View

13.

Steinman R, Kaplan G, Witmer M, COHN Z . Identification of a novel cell type in peripheral lymphoid organs of mice. V. Purification of spleen dendritic cells, new surface markers, and maintenance in vitro. J Exp Med. 1979; 149(1):1-16. PMC: 2184752. DOI: 10.1084/jem.149.1.1. View

14.

Castano P, Fuertes M, Ferre I, Fernandez M, Ferreras M, Moreno-Gonzalo J . Placental thrombosis in acute phase abortions during experimental Toxoplasma gondii infection in sheep. Vet Res. 2014; 45:9. PMC: 3931317. DOI: 10.1186/1297-9716-45-9. View

15.

Norbury L, Basalaj K, Zawistowska-Deniziak A, Sielicka A, Wilkowski P, Wesolowska A . Intranasal delivery of a formulation containing stage-specific recombinant proteins of Fasciola hepatica cathepsin L5 and cathepsin B2 triggers an anti-fecundity effect and an adjuvant-mediated reduction in fluke burden in sheep. Vet Parasitol. 2018; 258:14-23. DOI: 10.1016/j.vetpar.2018.05.008. View

16.

Regnault T, de Vrijer B, Galan H, Davidsen M, Trembler K, Battaglia F . The relationship between transplacental O2 diffusion and placental expression of PlGF, VEGF and their receptors in a placental insufficiency model of fetal growth restriction. J Physiol. 2003; 550(Pt 2):641-56. PMC: 2343042. DOI: 10.1113/jphysiol.2003.039511. View

17.

Innes E . Toxoplasmosis: comparative species susceptibility and host immune response. Comp Immunol Microbiol Infect Dis. 1997; 20(2):131-8. DOI: 10.1016/s0147-9571(96)00038-0. View

18.

Ferret-Bernard S, Remot A, Lacroix-Lamande S, Metton C, Bernardet N, Drouet F . Cellular and molecular mechanisms underlying the strong neonatal IL-12 response of lamb mesenteric lymph node cells to R-848. PLoS One. 2010; 5(10):e13705. PMC: 2965667. DOI: 10.1371/journal.pone.0013705. View

19.

Buxton D, Uggla A, Lovgren K, Thomson K, Lunden A, Morein B . Trial of a novel experimental Toxoplasma iscom vaccine in pregnant sheep. Br Vet J. 1989; 145(5):451-7. DOI: 10.1016/0007-1935(89)90053-5. View

20.

Owen M, Clarkson M, Trees A . Acute phase toxoplasma abortions in sheep. Vet Rec. 1998; 142(18):480-2. DOI: 10.1136/vr.142.18.480. View